Kidney damage in Covid-19: clinical-pathogenetic aspects and management of patients with chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In this review, we discuss the chronic immunological changes observed in patients with chronic kidney disease (ckd), the risk of covid-19 infection, and the clinical implications and specific covid-19 therapy in ckd patients. actually, the risk of severe covid-19 in ckd patients is з times higher than in patients without ckd; ckd in the intensive care unit is 12 times more common than in non-hospitalized patients with covid-19, and this ratio is higher than in patients with diabetes mellitus or cardiovascular diseases; and mortality rate from covid-19 is 15-25% among hemodialysis patients, even if pneumonia does not develop.

Full Text

Restricted Access

About the authors

Sherzod S. Abdullaev

Tashkent Paediatric Medical Institute

Email: dr.sherzod@rambler.ru
Dr. Sci. (Med.), Associate Professor at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID

Ranokhon Sh. Igamberdiyeva

Tashkent Paediatric Medical Institute

Email: rano1982@yandex.ru
Teaching Assistant at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID

Olimkhon N. Sharapov

Tashkent Paediatric Medical Institute; Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Email: olimkhon@gmail.com
Doctoral Student at the Department of Faculty Internal Diseases, Occupational Pathology, MFT, Hospital Internal Diseases and PID, Tashkent Pediatric Medical Institute

References

  1. Guan W.J., Ni Z.Y., Hu Y., et al. Clinical сharacteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708-20.
  2. Kwenandar F, Japar K.V., Damay V., et al. Coronavirus disease 2019 and cardiovascular system: A narrative review. Int. J. Cardiol. Heart Vasc. 2020;29:100557.
  3. Rubens J., Karakousis P., Sanjay J. Stability and viability of SARS-CoV-2. N. Engl. J. Med. 2020;382:1964.
  4. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 - United States, February 12-March 28, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69: 382-86.
  5. Cheng Y., Luo R., Wang K., et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829-38.
  6. Zou X., Chen K., Zou J., et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoVinfection. Front. Med. 2020;14:185-92.
  7. Pacciarini F., Ghezzi S., Canducci F., et al. Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. J. Virol. 2008;82:5137-44.
  8. Roca-Ho H., Riera M., Palau V., et al. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int. J. Mol. Sci. 2017;18:563.
  9. Anguiano L., Riera M., Pascual J., et al. Circulating angiotensinconverting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol. Dial. Transplant. 201530:1176-85.
  10. Riera M., Marquez E., Clotet S., et al. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS One. 2014;9:e84683.
  11. Naicker S., Yang C.-W., Hwang S.-J., et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97:824-28.
  12. Mancia G., Rea F., Ludergnani M., et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N. Engl. J. Med. 2020. http://www. nejm.org/doi/10.1056/NEJMoa2006923.
  13. Cheng Y., Luo R., Wang K., et al. Kidney impairment is associated with inhospital death of COVID-19 patients. Kidney Int. 2020;97:829-38.
  14. Martin-Sanchez D, Fontecha-Barriuso M., Carrasco S., et al. TWEAK and RIPK1 mediate a second wave of cell death during AKI. Proc. Natl. Acad. Sci. USA. 2018;115:4182-87.
  15. Su H, Yang M., Wan C., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020. https://linkinghub.elsevier.com/re trieve/pii/S0085253820303690.
  16. Pan Y., Zhang D., Yang P., et al. Viral load of SARS-CoV-2 in clinical samples. Lancet. Infect. Dis. 2020;20:411-12.
  17. Peleg Y., Kudose S., D’Agati V., et al. Acute kidney injury due to collapsing glomerulopathy following COVID-19 infection. Kidney Int. Rep. 2020. https:// linkinghub.elsevier.com/retrieve/pii/S2468024920312195.
  18. Heine G.H., Ortiz A., Massy Z.A., et al.Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat. Rev. Nephrol. 2012;8:362-69.
  19. Chonchol M. Neutrophil dysfunction and infection risk in end-stage renal disease. Semin. Dial. 2006;19:291-96.
  20. Meier P., Dayer E., Blanc E., et al. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002;13:204-12.
  21. Fernandez-Fresnedo G., Ramos M.A., Gonzalez-Pardo M.C., et al. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol. Dial. Transplant. 2000;15:502-10.
  22. Haag-Weber M., Ho"rl W.H. Dysfunction of polymorphonuclear leukocytes in uremia. Semin. Nephrol. 1996;16:192-201.
  23. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection ? Lancet. Respir. Med. 2020;8:e21.
  24. Gurwitz D. Angiotensin receptor blockers as tentative SARSCoV-2 therapeutics. Drug Dev. Res. 2020. http://www.ncbi.nlm. nih.gov/pubmed/32129518.
  25. Li G., Hu R., Zhang X. Antihypertensive treatment with ACEI/ ARB of patients with COVID-19 complicated by hypertension. Hypertens. Res. 2020;43:588-90.
  26. Monteil V., Kwon H., Prado P., et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905-13.e7.
  27. Rojas-Rivera J., de La Piedra C., Ramos A., et al. The expanding spectrum of biological actions of vitamin D. Nephrol. Dial. Transplant. 2010;25:2850-65.
  28. Ronco C., Reis T., de Rosa S. Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum. Blood Purif. 2020;49:255-58.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies